Related Experiment Video
Updated: Apr 30, 2026
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
Published on: February 23, 2024
Using Caenorhabditis elegans as a Model for Obesity Pharmacology Development
Jolene Zheng1, Joseph R Vasselli, Jason F King
11Department of Food Science, College of Agricultural Center, Louisiana State University, Baton Rouge, LA; 2Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, LA; 3Columbia University, New York, NY; 4Department of Biological Science, College of Sciences, Louisiana State University, Baton Rouge, LA; 5Department of Environment, School of Life Sciences, Fudan University, Shanghai, China; and 6University of California, Davis One Shields Avenue Davis, CA.
The nematode Caenorhabditis elegans effectively models drug effects on fat deposition, aiding obesity drug discovery. This research demonstrates its utility in identifying drug mechanisms and effective treatment ratios.
Area of Science:
- Pharmacology
- Genetics
- Obesity Research
Background:
- The nematode Caenorhabditis elegans (C. elegans) offers a rapid and cost-effective model for pharmacological research.
- Investigating candidate anti-obesity drugs requires efficient screening and mechanism-of-action studies.
Purpose of the Study:
- To explore the utility of C. elegans in addressing two key pharmacological questions related to anti-obesity drug development.
- To determine an effective betahistine-olanzapine ratio to counteract olanzapine-induced intestinal fat deposition (IFD).
- To identify the mechanism of action for pharmaceutical candidate AB-101, which reduces IFD.
Main Methods:
- Utilized wild-type (N2) and mutant C. elegans strains.
- Quantified intestinal fat deposition (IFD) using Nile red staining.
- Assessed drug effects on IFD, pharyngeal pumping rate, and responses to protease inhibitors (atazanavir, ritonavir).
Main Results:
- Olanzapine significantly increased IFD in N2 worms, an effect blocked by betahistine.
- AB-101 reduced IFD, increased pharyngeal pumping rate, and reversed IFD elevated by protease inhibitors.
- AB-101's lack of effect on IFD in an ACS null mutant suggests involvement of the lipid oxidation pathway and CPT-1 upregulation.
Conclusions:
- C. elegans serves as a valuable model organism for pharmacological research, particularly in anti-obesity drug development.
- The study successfully identified a therapeutic ratio for betahistine-olanzapine and elucidated potential mechanisms for AB-101.
- C. elegans facilitates the discovery and characterization of novel pharmaceutical interventions.
